期刊
NEUROLOGY
卷 80, 期 3, 页码 296-303出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31827debad
关键词
-
资金
- Research Commission of the Heinrich-Heine-University
- ECTRIMS (European Conference on Research and Treatment of MS)
- Fritz-Thyssen Foundation
- Bayer Schering
- Biogen Idec
- Merck Serono
- Teva Neuroscience
Objective: To investigate changes in the T-cell repertoire in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) without and with treatment of IV immunoglobulins (IVIg). Methods: The T-cell receptor (TCR) repertoire of CD4+ and CD8+ T cells in the peripheral blood was analyzed using CDR3 spectratyping. Patients with CIDP were included without (n = 14) and with IVIg treatment (n = 11) cross-sectionally and longitudinally (n = 2). Results: While the TCR length distribution of patients with CIDP was only moderately altered for most of the V beta elements of CD4+ T cells, the CD8+ population displayed extensive oligoclonal expansions in all analyzed 24 V beta elements. A public expansion of a distinct TCR length in one V beta element within a majority of affected patients was not detectable. Treatment with IVIg reduced the oligoclonal expansions within both the CD4+ and CD8+ population. Conclusions: Our data demonstrate that cytotoxic CD8+ T cells exhibit a much broader activation than CD4+ T cells, indicating a potentially crucial role of CD8+ T cells in the immunopathogenesis of CIDP. The profound oligoclonal response in T-cell activation suggests that multiple peptides may induce and propagate this autoimmune-driven disease. The observed reduction of highly activated T cells may contribute to the therapeutic effects of IVIg. Neurology (R) 2013;80:296-303
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据